Second Genome and Evotec to collaborate in microbiome discovery and development
As part of the collaboration, Second Genome and Evotec will work together to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec's technology platform, chemical libraries and other pre-clinical capabilities. The agreement between Evotec and Second Genome triggers an undisclosed upfront payment. Evotec is also eligible for pre-clinical, clinical and regulatory milestones as well as royalty payments related to commercialisation.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are pleased to contribute to Second Genome's unique approach to treat microbiome-mediated diseases in the body with a particular emphasis on the gut. The enrichment and maturation of Second Genome's project portfolio through our contributions will enhance the Company's clinical pipeline in the near future."
Mohan Iyer, Chief Business Officer of Second Genome, added: "The partnership with Evotec allows us efficiently to translate our unique microbiome discovery platform efficiently into tangible drug molecules for clinical development. Our enriched pipeline offers new treatment approaches for patients across a wide range of diseases with an initial focus on inflammatory conditions. We look forward to a sustained partnership with Evotec."
Further financial terms were not disclosed.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.